Pretreatment serum levels of bFGF and VEGF and its clinical significance in endometrial carcinoma

Gynecologic Oncology

Volumn 128, Issue 3, 2013, Pages 454-460

  Dobrzycka, Bozena ^a   MacKowiak Matejczyk, Beata ^b   Kinalski, MacIej ^c   Terlikowski, Slawomir Jerzy ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b Department of Gynecologic Oncology   (Poland)

^c District General Hospital Bialystok   (Poland)

Author keywords

bFGF; Endometrial cancer; Prognostic factors; Survival; VEGF

Indexed keywords

FIBROBLAST GROWTH FACTOR 2; VASCULOTROPIN;

ADULT; ARTICLE; CANCER INVASION; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ENDOMETRIUM CARCINOMA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TREATMENT RESPONSE;

ADULT; AGED; ENDOMETRIAL NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; MIDDLE AGED; PROGNOSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 84873735241     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2012.11.035     Document Type: Article

References (25)

1. D.M. Parkin, F. Bray, J. Ferlay, and P. Pisani Global cancer statistics, 2002 CA Cancer J Clin 55 2 2005 74 108
2. J. Didkowska, U. Wojciechowska, and W. Zatoński Nowotwory złośliwe w Polsce w 2009 roku 2011 Centrum Onkologii Instytut Warszawa
3. F. Amant, P. Moerman, P. Neven, D. Timmerman, E. Van Limbergen, and I. Vergote Endometrial cancer Lancet 366 9484 2005 491 505
4. S. Vance, R. Yechieli, C. Cogan, R. Hanna, A. Munkarah, and M.A. Elshaikh The prognostic significance of age in surgically staged patients with type II endometrial carcinoma Gynecol Oncol 126 1 2012 16 19
5. G. Plataniotis, M. Castiglione, and ESMO Guidelines Working Group Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 21 Suppl. 5 2010 v41 v45
6. J.D. Wright, N.I. Barrena Medel, J. Sehouli, K. Fujiwara, and T.J. Herzog Contemporary management of endometrial cancer Lancet 379 9823 2012 1352 1360
7. R. Roskoski Jr. Vascular endothelial growth factor (VEGF) signaling in tumor progression Crit Rev Oncol Hematol 62 3 2007 179 213
8. M. Przybylski A review of the current research on the role of bFGF and VEGF in angiogenesis J Wound Care 18 12 2009 516 519
9. J. Fujimoto Novel therapeutic strategy for uterine endometrial cancers Int J Clin Oncol 13 2008 411 415
10. M.I. Koukourakis, V. Limberis, I. Tentes, E. Kontomanolis, A. Kortsaris, and E. Sivridis Serum VEGF levels and tissue activation of VEGFR2/KDR receptors in patients with breast and gynecologic cancer Cytokine 53 3 2011 370 375
11. B. Dobrzycka, S.J. Terlikowski, M. Kwiatkowski, M. Garbowicz, M. Kinalski, and L. Chyczewski Prognostic significance of VEGF and its receptors in endometrioid endometrial cancer Ginekol Pol 81 6 2010 422 425
12. M. Hirai, A. Nakagawara, T. Oosaki, Y. Hayashi, M. Hirono, and T. Yoshihara Expression of vascular endothelial growth factors (VEGF-A/VEGF-1 and VEGF-C/VEGF-2) in postmenopausal uterine endometrial carcinoma Gynecol Oncol 80 2 2001 181 188
13. Y. Yokoyama, S. Sato, M. Futagami, Y. Fukushi, T. Sakamoto, and M. Umemoto Prognostic significance of vascular endothelial growth factor and its receptors in endometrial carcinoma Gynecol Oncol 77 3 2000 413 418
14. A. Mazurek, P. Pierzyński, P. Kuć, P. Kopinski, S. Terlikowski, and W. Niklińska Evaluation of angiogenesis, p-53 tissue protein expression and serum VEGF in patients with endometrial cancer Neoplasma 51 3 2004 193 197
15. B. Dobrzycka, S.J. Terlikowski, O. Kowalczuk, M. Kulikowski, and J. Niklinski Serum levels of VEGF and VEGF-C in patients with endometrial cancer Eur Cytokine Netw 22 1 2011 45 51
16. B. Dobrzycka, and S.J. Terlikowski Biomarkers as prognostic factors in endometrial cancer Folia Histochem Cytobiol 48 3 2010 319 322
17. S. Kondo, M. Asano, K. Matsuo, I. Ohmori, and H. Suzuki Vascular endothelial growth factor/vascular permeability factor is detectable in the sera of tumor-bearing mice and cancer patients Biochim Biophys Acta 1221 2 1994 211 214
18. M. Shaarawy, and S.A. El-Sharkawy Biomarkers of intrinsic angiogenic and anti-angiogenic activity in patients with endometrial hyperplasia and endometrial cancer Acta Oncol 40 4 2001 513 518
19. C.A. Chen, W.F. Cheng, C.N. Lee, L.H. Wei, J.S. Chu, and F.J. Hsieh Cytosol vascular endothelial growth factor in endometrial carcinoma: correlation with disease-free survival Gynecol Oncol 80 2 2001 207 212
20. A. Giatromanolaki, E. Sivridis, R. Brekken, P.E. Thorpe, P. Anastasiadis, and K.C. Gatter The angiogenic "vascular endothelial growth factor/flk-1(KDR) receptor" pathway in patients with endometrial carcinoma: prognostic and therapeutic implications Cancer 92 10 2001 2569 2577
21. A.A. Kamat, W.M. Merritt, D. Coffey, Y.G. Lin, P.R. Patel, and R. Broaddus Clinical and biological significance of vascular endothelial growth factor in endometrial cancer Clin Cancer Res 13 24 2007 7487 7495
22. R.J. Gornall, F.W. Anthony, E.J. Coombes, P. Hogston, and R.P. Woolas Investigation of women with endometrial carcinoma using serum vascular endothelial growth factor (VEGF) measurement Int J Gynecol Cancer 11 2 2001 164 166
23. D.S. McMeekin, M.W. Sill, D. Benbrook, K.M. Darcy, D.J. Stearns-Kurosawa, and L. Eaton A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study Gynecol Oncol 105 2 2007 508 516
24. C. Kut, F. Mac Gabhann, and A.S. Popel Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer Br J Cancer 97 7 2007 978 985
25. K. Fujimoto, Y. Ichimori, T. Kakizoe, E. Okajima, H. Sakamoto, and T. Sugimura Increased serum levels of basic fibroblast growth factor in patients with renal cell carcinoma Biochem Biophys Res Commun 180 1 1991 386 392